Abstract
Major depressive disorder (MDD) is a prevalent illness in minority populations. Minority patients with MDD are often unrecognized and untreated. This review examines promising interventions to address MDD in primary care settings, where minority groups are more likely to seek care. Since 2010, eleven interventions have been developed to address patient-specific and provider-specific barriers, many of which are adaptations of the collaborative care model. Other promising interventions include cultural tailoring of the collaborative care model, as well as the addition of telepsychiatry, motivational interviewing, cultural consultation, and innovations in interpreting. Overall, collaborative care was found feasible and improved satisfaction and treatment engagement of depressed minority patients in primary care. It remains inconclusive whether these newer intervention models improve MDD treatment outcomes. Future research will be needed to establish the effectiveness of these intervention models in improving the treatment outcomes of minority populations with MDD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Kessler RC, Berglund PB, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;18:3095–105.
Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465–75.
Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA. 2003;289:3135–44.
Young CB, Fang DZ, Zisook S. Depression in Asian-American and Caucasian undergraduate students. J Affect Disord. 2010;125:379–82.
• Gonzalez HM, Vega WA, Williams DR, et al. Depression care in the United States. Arch Gen Psychiatry 2010, 67:37–46. This study used existing survey data to analyze differences in depression treatment across minority populations. The study found that Mexican American and African American patients were less likely than non-Latino white patients to receive any kind of depression treatment.
Gonzalez HM, Tarraf W, Whitfield KE, et al. The epidemiology of major depression and ethnicity in the United States. J Psychiatr Res. 2010;44:1043–51.
Yeung A, Kung WW, Murakami JL, et al. Outcomes of recognizing depressed Chinese American patients in primary care. Int J Psychiatry Med. 2005;35:213–24.
Dwight-Johnson M, Lagomasino IT, Hay J, et al. Effectiveness of collaborative care in addressing depression treatment preferences among low-income Latinos. Psychiatr Serv. 2010;61:1112–8.
• Lesser IM, Zisook S, Gaynes BN, et al. Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. Psychiatr Serv 2011, 62:1167–79. This study found that African American patients were more likely than Latino and non-Latino white patients to leave the study early.
Yeung A, Kung WW, Chung H, et al. Integrating psychiatry and primary care improves acceptability to mental health services among Chinese Americans. Gen Hosp Psychiatry. 2004;26:256–60.
Meadows T, Valleley R, Haack MK, et al. Physician “costs” in providing behavioral health in primary care. Clin Pediatr. 2011;50:447–55.
Costello EJ, Keeler GP, Angold A. Poverty, race/ethnicity, and psychiatric disorder: a study of rural children. Am J Public Health. 2001;91:1494–8.
Kaltman S, Pauk J, Alter CL. Meeting the mental health needs of low-income immigrants in primary care: a community adaptation of an evidence-based model. Am J Orthopsychiatry. 2011;81:543–51.
Bhui K, Bhugra D, Goldberg D, et al. Cultural influences on the prevalence of common mental disorder, general practitioners’ assessments and help-seeking among Punjabi and English people visiting their general practitioner. Pscyhol Med. 2001;31:815–25.
Mezzich JE, Raab ES. Depressive symptomatology across the Americas. Arch Gen Psychiatry. 1980;37:818–23.
Jimenez DE, Bartels SJ, Cardenas V, et al. Cultural beliefs and mental health treatment preferences of ethnically diverse older adult consumers in primary care. Am J Geriatr Psychiatry, 2011; doi:10.1097/JGP.0b013e318227f876.
• Vega WA, Rodriguez, MA, Ang A. Addressing stigma of depression in Latino primary care patients. Gen Hosp Psychiatry 2010 32:182–191. Findings of the study indicate that Latino patients who report a high degree of stigma may be less likely to receive treatment for depression and are also less likely to share their depression with family and friends.
Kasckow J, Ingram E, Brown C, et al. Differences in treatment attitudes between depressed African-American and Caucasian veterans in primary care. Psychiatr Serv. 2011;62:426–9.
Interian A, Martinez I, Rios LI, et al. Adaptation of a motivational interviewing intervention to improve antidepressant adherence among Latinos. Cultur Divers Ethnic Minor Psychol. 2010;16:215–25.
Miranda J, Cooper LA. Disparities in care for depression among primary care patients. J Gen Intern Med. 2004;19:120–6.
• Fortuna LR, Alegria M, Gao S. Retention in depression treatment among ethnic and racial minority groups in the United States. Depress Anxiety 2010, 27:485–94. In this analysis of existing data, African American patients were least likely to be retained in depression care compared with non-Latino white, Latino American, African American, and Asian American patients. All patients were more likely to remain in care for depression if they saw a mental health specialist as opposed to a primary care doctor.
Bao Y, Alexopoulous GS, Casalino LP, et al. Collaborative depression care management and disparities in depression treatment and outcomes. Arch Gen Psychiatry 2011;68:627–636.
Huang H, Chan YF, Katon W, et al. Variations in depression care and outcomes among high-risk mothers from different racial/ethnic groups. Fam Pract 2011; doi:10.1093/fampra/cmr108.
Yeung A, Shyu I, Fisher L, et al. Culturally sensitive collaborative treatment for depressed Chinese Americans in primary care. Am J Public Health. 2010;100:2397–402.
Kwong K, Chung H, Cheal K, et al. Depression care management for Chinese Americans in primary care: a feasibility pilot study. Community Ment Health J 2011. doi:10.1007/s10597-011-9459-9.
Cooper LA, Ford DE, Ghods BK, et al. A cluster randomized trial of standard quality improvement versus patient-centered interventions to enhance depression care for African Americans in the primary care setting: study protocol NCT00243425. Implement Sci. 2010;5:18.
Leng JC, Changrani J, Tseng CH, et al. Detection of depression with different interpreting methods among Chinese and Latino primary care patients: a randomized controlled trial. J Immigr Minor Health. 2010;12:234–41.
Yeung A, Hails K, Chang T, et al. A study of the effectiveness of telepsychiatry-based culturally sensitive collaborative treatment of depressed Chinese Americans. BMC Psychiatry. 2011;11:154.
Trinh NH, Bedoya CA, Chang TE, et al. A study of a culturally focused psychiatric consultation service for Asian American and Latino American primary care patients with depression. BMC Psychiatry. 2011;11:166.
Pan D, Huey SJ, Hernandez D. Culturally adapted versus standard exposure treatment for phobic Asian Americans: treatment efficacy, moderators, and predictors. Cultur Divers Ethnic Minor Psychol. 2011;17:11–22.
Hinton DE, Hofmann SG, Rivera E, et al. Culturally adapted CBT (CA-CBT) for Latino women with treatment-resistant PTSD: a pilot study comparing CA-CBT to applied muscle relaxation. Behav Res Ther. 2011;49:275–80.
Wu D, Ma GX, Zhou K, et al. The effect of culturally tailored smoking cessation for Chinese American smokers. Nicotine Tob Res. 2009;11:1448–57.
Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA. 1995;273:1026–31.
Unützer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288:2836–45.
Schulberg HC, Bryce C, Chism K, et al. Managing late-life depression in primary care practice: a case study of the health specialist’s role. Int J Geriatr Psychiatry. 2001;16:577–84.
Yeung A, Yu SC, Fung F, et al. Recognizing and engaging depressed Chinese Americans in treatment in a primary care setting. Int J Geriatr Psychiatry. 2006;21:819–23.
Yeung A, Trinh NH, Chang TE, et al. The Engagement Interview Protocol (EIP): improving the acceptance of mental health treatment among Chinese immigrants. Int J Cult Ment Health. 2011;4:91–105.
Miller WR, Rollnick S. Motivational interviewing: preparing people for change, 2nd edition]. New York: The Guilford Press; 2002.
Disclosure
Drs. Hails, Brill, Yeung, and reported no potential conflicts of interest.
Dr. Chang has served as a consultant for OptumInsight; has received research support from AstraZeneca, CeNeRx BioPharma, Euthymics Bioscience, Forest Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, and Pfizer; and has received honoraria from and had travel/accommodations expenses covered/reimbursed by Bristol-Myers Squibb.
Dr. Fava has received equity holdings from Compellis; has received royalties from Lippincott Williams & Wilkins, Wolters Kluwer, and World Scientific Publishing; has received compensation for editing from Belvoir Media Group, Massachusetts General Hospital Psychiatry Academy, CME Institute/Physicians Postgraduate Press, and Association for Health Research & Development (ACINDES); has received honoraria from Eisai, Johnson & Johnson Pharmaceutical Research & Development, Lundbeck, Pfizer, and Servier Laboratories; has served as a board member of BrainCells, Bristol-Myers Squibb, Eisai, EnVivo Pharmaceuticals, Ganeden Biotech, Genomind, Johnson & Johnson, Lundbeck/Takeda, National Institute on Drug Abuse (NIDA), Neuronetics, PsychoGenics, Psylin Neurosciences, Schering-Plough, Transcept Pharmaceuticals; has received patents for Sequential Parallel Comparison Design (SPCD), a patent for research and licensing of SPCD with RCT Logic, a patent application for a combination of azapirones and bupropion in major depressive disorder (MDD), and copyright royalties for the MGH Cognitive and Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), and SAFER; has received research support from National Institute of Mental Health (NIMH), National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health (NIH), NIDA, Bristol-Myers Squibb, Ganeden Biotech, Johnson & Johnson, Pamlab, Clinical Trials Solutions, Pfizer Forest, CeNeRx BioPharma, i3Research, Euthymics Bioscience, Covance, GlaxoSmithKline, AstraZeneca, Novartis, Roche, and Sanofi-Aventis; and has served as a consultant for Abbott Laboratories, Affectis Pharmaceuticals, Alkermes, Amarin Pharma, Aspect Medical Systems, AstraZeneca, Auspex Pharmaceuticals, Bayer, Best Practice Project Management, BioMarin Pharmaceutical, Biovail Corporation, BrainCells, Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon, Clinical Trials Solutions, CNS Response, Compellis Pharmaceuticals, Cypress Pharmaceutical, DiagnoSearch Life Sciences, Dainippon Sumitomo Pharma, DOV Pharmaceutical, Edgemont Pharmaceuticals, Eisai, Eli Lilly and Company, EnVivo Pharmaceuticals, ePharmaSolutions, EPIX Pharmaceuticals, Euthymics Bioscience, Fabre-Kramer Pharmaceuticals, Forest Pharmaceuticals, Genomind, GlaxoSmithKline, Grünenthal, i3 Innovus/Ingenis, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, Knoll Pharmaceuticals, Labopharm, Lorex Pharmaceuticals, Lundbeck, MedAvante, Merck & Co., MSI Methylation Sciences, Naurex; Neuronetics, NextWave Pharmaceuticals, Novartis, Nutrition 21, Orexigen Therapeutics, Organon Pharmaceuticals, Otsuka Pharmaceuticals, Pamlab, Pfizer, PharmaStar, Pharmavite, PharmoRx Therapeutics, Precision Human Biolaboratory, Prexa Pharmaceuticals, Puretech Ventures, PsychoGenics, Psylin Neurosciences, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche, RCT Logic, Sanofi-Aventis, Sepracor, Servier Laboratories; Schering-Plough, Solvay Pharmaceuticals, Somaxon Pharmaceuticals, Somerset Pharmaceuticals, Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Synthelabo, Takeda, Tal Medical, Tetragenex Pharmaceuticals, TransForm Pharmaceuticals, Transcept Pharmaceuticals, Vanda Pharmaceuticals.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hails, K., Brill, C.D., Chang, T. et al. Cross-Cultural Aspects of Depression Management in Primary Care. Curr Psychiatry Rep 14, 336–344 (2012). https://doi.org/10.1007/s11920-012-0276-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11920-012-0276-9